PURE Bioscience, Inc. has announced a successful closing of a private placement financing, raising $555,000 from accredited investors. This significant funding will support the company’s ongoing research and development efforts as well as general corporate purposes.
The financing involved the issuance of 10,183,486 shares of common stock at a price of $0.0545 per share. Notably, Tom Y. Lee, a member of the company's Board of Directors, invested the entire amount directly and through affiliates, indicating strong internal confidence in the company's direction.
Company Overview
PURE Bioscience, Inc. operates in the Miscellaneous Chemical Products sector, focusing on innovative antimicrobial solutions. The company is known for its patented silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent. PURE is listed under the ticker symbol "PURE" on the OTC exchange and is classified as a smaller reporting company.
Details from the Filing
The filing dated October 20, 2026, outlines the completion of the private placement financing which took place on October 15, 2026. According to the filing, the net proceeds from this financing, after deducting fees, are expected to be approximately $555,000. The funds will be allocated towards the company’s research and development, administrative expenses, and working capital needs.
The shares were issued under a Securities Purchase Agreement, and the transaction was approved by the disinterested members of the Board. The filing also notes that the shares were not registered under the Securities Act of 1933, and thus cannot be offered or sold in the U.S. without proper registration or exemption.
Potential Impact
This financing could significantly impact PURE Bioscience's operational capabilities, particularly in research and development, which is crucial for innovation in the competitive chemical products industry. The infusion of capital may enable the company to accelerate its product development and enhance its market position.
What's Next?
The filing does not specify what happens next for the company following this financing round. However, the successful capital raise indicates a positive outlook for future initiatives and projects.